Get the Stockscreener App
7.69
1.85%
0.14
After Hours:
7.65
-0.04
-0.52%
Aurinia Pharmaceuticals Inc stock is traded at $7.69, with a volume of 1.12M.
It is up +1.85% in the last 24 hours and down -17.93% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
See More
Previous Close:
$7.55
Open:
$7.73
24h Volume:
1.12M
Relative Volume:
0.84
Market Cap:
$1.10B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-14.51
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
-7.79%
1M Performance:
-17.93%
6M Performance:
+35.63%
1Y Performance:
-0.65%
1-Day Range:
$7.61
$7.78
1-Week Range:
$7.52
$8.27
52-Week Range:
$4.71
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
7.69 | 1.10B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.26 | 109.26B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.43 | 77.30B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.19 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.01 | 32.38B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.67 | 27.25B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
AUPH: Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space? - StockNews.com
Barclays PLC Boosts Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded by StockNews.com to Strong-Buy Rating - MarketBeat
Long Term Trading Analysis for (AUPH) - Stock Traders Daily
New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights - GlobeNewswire Inc.
Aurinia Pharmaceuticals (NASDAQ:AUPH shareholders incur further losses as stock declines 5.2% this week, taking five-year losses to 57% - Simply Wall St
Franklin Resources Inc. Sells 75,024 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
Barclays PLC Acquires 143,072 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals laying off dozens in Montgomery County - The Business Journals
State Street Corp Has $21.59 Million Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
(AUPH) On The My Stocks Page - Stock Traders Daily
Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 9.6% - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Charles Schwab Investment Management Inc. Grows Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $10M Stock Buy: Retail Confidence Spikes - MSN
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25% - Simply Wall St
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options - MSN
Aurinia Pharma stock hits 52-week high at $9.76 - Investing.com
Aurinia Pharma stock hits 52-week high at $9.76 By Investing.com - Investing.com UK
Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares - Investing.com India
Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares By Investing.com - Investing.com Australia
(AUPH) Investment Analysis - Stock Traders Daily
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership - Yahoo Finance
We Might See A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Soon - Simply Wall St
PDT Partners LLC Buys 130,204 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Algert Global LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - MSN
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - sharewise
(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - sharewise
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ARMISTICE CAPITAL, LLC's Strategic Reduction in Aurinia Pharmace - GuruFocus.com
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.31%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):